COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies
Approval is supported by data from the EMERGENT clinical program demonstrating statistically significant reductions of schizophrenia symptoms
The safety and tolerability profile of COBENFY has been established across acute and long-term trials in schizophrenia
Continue reading
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) — Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane Award from the Arizona Bioindustry Association (AZBio). Each year a select group of Arizona-based life science companies are recognized for the progress they are making to develop and deliver health innovations. Nectero Medical accepted the award at the 20th Annual AZBio Awards Dinner held on Wednesday, September 18th at the Phoenix Convention Center as part of Arizona Bioscience Week, which is presented by AZBio and the Arizona Commerce Authority.Continue reading
Focus on Lyme and Tulane University License Groundbreaking Diagnostic Technology to Aces Diagnostics Inc.Continue reading
LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, has received a historic $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and his daughter Tessa Stephenson Brand to immediately fund pancreatic cancer research. Continue reading
PHOENIX, ARIZ, September 17, 2024 – Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis & Dionne Professor of Neurological Surgery, has been recognized as the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. He will receive the award at the 20th Annual AZBio Awards on Wednesday, September 18 at the Phoenix Convention Center. Dr. Sanai is being honored for his pioneering spirit and commitment to push beyond the status quo to discover new therapies for his brain tumor patients. Continue reading
PHOENIX and FRIENDSWOOD, TX – Sept. 16, 2024 – The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, presented by AZBio, recognizes Oelschlager for her outstanding leadership that has contributed significantly to the progression of the bioscience industry in Arizona.Continue reading
WASHINGTON, Sept. 12, 2024 — Critical Path Institute (C-Path) successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024, at the Washington Marriott at Metro Center in Washington, D.C. This landmark event brought together industry leaders, regulatory agencies, academic experts, and patient advocacy groups, all dedicated to advancing drug development and regulatory science for rare diseases. Continue reading
Tucson, AZ — University of Arizona Center for Innovation (UACI) is proud to announce that Macula Vision Systems, a pioneer in clinical microscopy, continues to gain momentum as it advances in both national and international stages of the life sciences industry. Macula Vision Systems is based out of UACI at Oro Valley, Arizona – an incubator focused on supporting bioscience startups by providing specialized lab space and tailored business development programming. In recent and upcoming weeks, the company proudly stands out by participating in prestigious programs and pitch competitions, highlighting its groundbreaking advancements in high-throughput imaging and automated interpretation technologies.Continue reading
